Amarin Corp Plc (AMRN)

[HDGabor]

r-

In statin naive patients there may have been much better potential for success than in patients already taking - and success here would have opened the door for direct competition against statins

THIS IS A MAJOR FLAW AND MAY COST INVESTORS HUGELY

If R-IT is with statin naive patients and successful: Would you (prescribers) like (have enough proof) to subscribe V as add-in for patients already taking statin? Or not?

If R-IT is with statin naive patients and successful: Would you (prescribers) like (have enough proof) to subscribe V instead of statin? Or not?

If R-IT (as it is) is successful: Would you (prescribers) like (have enough proof) to subscribe V for statin naive patients? Or not?

If you answer honestly, you will know why is the design (patients already taking statin) what it is.

Best,
G